TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30005643
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support intervention with monthly group education on diabetic retinopathy (DR) and individual reminders for eye examination
Study: 28511614
Drug: NTP-CE (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTP-CE (new topical panthenol-containing emollient)
Study: 25626962
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (group C)
Study: 12535822
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/daily
Study: 12535822
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/daily
Study: 10825055
Drug: Thalidomide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (400 mg/d for 1 week, then 200 mg/d for 7 weeks)
Study: 2125605
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg once daily for 1 week
Study: 2125605
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg once daily for 1 week
Study: 29460236
Drug: XEN-D0103 50
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN-D0103 50 mg bd
Study: 1951080
Drug: OPC‐8212 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC‐8212 (60 mg/day)
Study: 6974386
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine against Hemophilus influenzae type b
Study: 17760597
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNTA) injections at the vermilion border, 1 week before chemabrasion
Study: 17760597
Drug: Control sides
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control sides (no BoNTA injections)
Study: 11169020
Drug: High-dose L-5-methyltetrahydrofolate
Normalized name: L-5-methyltetrahydrofolate
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose L-5-methyltetrahydrofolate (MTHF) at 17 mg/day
Study: 11169020
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) at 15 mg/day
Study: 11169020
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) at 2.4 mg/day (for RTRs)
Study: 11169020
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral MTHF (17 mg/day) or FA (15 mg/day) (for HD patients)
Study: 9701162
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn with micronutrients (ZM)
Study: 9701162
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Zn alone (Z)
Study: 2812836
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural administration of fentanyl (1 microgram/kg body weight)
Study: 2812836
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of fentanyl (1 microgram/kg body weight)
Study: 970905
Drug: Furosemide prophylaxis
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide prophylaxis (20-60 mg) in the short-perfusion group (9 patients)
Study: 970905
Drug: Furosemide prophylaxis
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide prophylaxis (20-60 mg) in the long-perfusion group (13 patients)
Study: 22208783
Drug: Piroxicam 10
Normalized name: piroxicam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 10 mg daily
Study: 18582572
Drug: Amoxicillin under
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin under fasting conditions
Study: 18582572
Drug: Amoxicillin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin after intake at the beginning of breakfast
Study: 18582572
Drug: Amoxicillin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin after breakfast
Study: 1363664
Drug: Psychosomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic therapy (psychotherapy, relaxation, etc.) alone in group I (9 patients)
Study: 1363664
Drug: Psychosomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic therapy plus treatment with amineptine and clobazam in group II (9 patients)
Study: 3910303
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg + Acebutolol 100 mg
Study: 27485432
Drug: Conventional Treatment
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatment (CT) using bulk fill composite resin (Scotchbond™ Universal Adhesive system associated with Filtek Bulk Fill - 3 M/ESPE)
Study: 27485432
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) using high viscosity glass ionomer cement (Ketac Molar Easy Mix - 3 M/ESPE)
Study: 24262503
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (target cyclosporine level 600-700 ng/ml for first 6 months, 450-550 ng/ml for next 18 months)
Study: 24262503
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (target cyclosporine level 450-550 ng/ml for first 6 months, 300-400 ng/ml for next 18 months)
Study: 22993341
Drug: Oral azasetron
Normalized name: alosetron Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azasetron
Study: 18806056
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg/mL)
Study: 18806056
Drug: Hydromorphone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (0.2 mg/mL)
Study: 12075577
Drug: PEG-OB (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-OB (60 mg weekly for 8 weeks)
Study: 2537721
Drug: NaHCO3 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (300 mg.kg‐1 body mass)
Study: 2537721
Drug: CaCO3 (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCO3 (placebo, 300 mg.kg‐1 body mass)
Study: 6455388
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin phosphate
Study: 6455388
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline hydrochloride
Study: 26264173
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise during hemodialysis sessions with ankle weights and resistance bands, performed twice a week for 12 weeks
Study: 20854696
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block injection
Study: 17986319
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment followed by functional rehabilitation with use of a functional bracing system
Study: 12032722
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cyclosporine A (15 mg/kg/day for 2 days, 7.5 mg/kg/day for 2 days, then adjusted to maintain trough blood levels of 100-200 microg/l)
Study: 12032722
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporine A (2 mg/kg/day with no loading dose)
Study: 2696890
Drug: Ceftazidime i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime i.v. (2 g) in three doses (half an hour before surgery, 8 and 16 hours from the first dose)
Study: 2696890
Drug: Netilmicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (100 mg) plus clindamycin (600 mg i.v.), following the same chronological schedule
Study: 330290
Drug: Lentizol 50
Normalized name: Lentizol 50 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentizol 50 mg
Study: 330290
Drug: Tryptizol 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptizol 75 mg
Study: 29283612
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment minimal contact control
Study: 21345470
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham treatment with disconnected magnet therapy device)
Study: 10831175
Drug: Slow-release lanreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release lanreotide (SR-L) 30 mg
Study: 9505983
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 to 80 mg)
Study: 9505983
Drug: Prednisolone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1.25 to 100 mg)
Study: 9505983
Drug: Prednisolone (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (multiple doses)
Study: 8415211
Drug: MC pork
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC pork insulin
Study: 22796996
Drug: Contrast bath
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast bath therapy
Study: 22796996
Drug: Cold water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold water immersion and contrast bath therapy
Study: 9821025
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (UFH)
Study: 12574806
Drug: Subcutaneous low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low-molecular-weight heparin (reviparin) twice daily for one week
Study: 12574806
Drug: Subcutaneous reviparin
Normalized name: reviparin
DrugBank: Reviparin (DB09259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous reviparin once daily for four weeks
Study: 12574806
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for at least 3 months
Study: 8832013
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of low-dose heparin (100 units/kg/day) from the first day of the preparative regimen to day +30 or until discharge.
Study: 1848167
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (0.5 and 1.0 ng min-1 kg-1)
Study: 30367457
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A at the optimal phase I‐II dose
Study: 30367457
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment C
Study: 29247172
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (60 mg iron as ferrous fumarate daily)
Study: 17322539
Drug: pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemetrexed 500 mg/m(2)
Study: 17322539
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m(2)
Study: 17322539
Drug: first-line therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: first-line therapy types (gemcitabine + platinum, taxane + platinum, other therapies)
Study: 15803358
Drug: Clodronate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate treatment
Study: 12225716
Drug: Diltiazem (Adizem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (Adizem XL) 300 mg once daily
Study: 12225716
Drug: Amlodipine/atenolol during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/atenolol during drug-free interval
Study: 10212715
Drug: Alfentanil 5
Normalized name: alfentanil 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 5 micrograms.kg‐1 and propofol 2.5 mg.kg‐1 (Group A5)
Study: 10212715
Drug: Alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 10 micrograms.kg‐1 and propofol 2.5 mg.kg‐1 (Group A10)
Study: 10212715
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg.kg‐1 only (Group P)
Study: 7600753
Drug: Structured teaching
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured teaching and treatment programme
Study: 1516498
Drug: Gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil treatment (n = 59)
Study: 6337667
Drug: Emepronium bromide
Normalized name: emepronium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium bromide 200 mg qid
Study: 6337667
Drug: Flavoxate chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavoxate chloride 200 mg qid
Study: 29735474
Drug: Multicomponent technology‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent technology‐based intervention targeting adherence to daily controller medication (2 sessions of computer‐delivered motivational interviewing and individualized text messaging)
Study: 24289574
Drug: Basant polyherbal
Normalized name: Bavisant
DrugBank: Bavisant (DB12299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basant polyherbal vaginal cream
Study: 24289574
Drug: Curcumin vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin vaginal capsules
Study: 24289574
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal cream
Study: 24289574
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal capsules
Study: 21986570
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of calcium L-threonate (675, 2025, or 4050 mg)
Study: 21986570
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of calcium L-threonate (2025 mg twice daily for 4 days)
Study: 21986570
Drug: Cumulative urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative urinary excretion of L-threonate
Study: 19065098
Drug: Evidence-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based intervention for dementia caregivers, details on dosage and duration not available.
Study: 19065098
Drug: Volunteer program,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteer program, details on dosage and duration not available.
Study: 11558843
Drug: Oral slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral slow-release isosorbide dinitrate (ISDN) 20 mg three times a day
Study: 3972221
Drug: Ileal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ileal infusion of Intralipid
Study: 30803843
Drug: Inactivated enterovirus
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated enterovirus A71 vaccine, administered in two doses with a 28-day or 56-day interval, booster dose at one year for participants aged two months to <two years
Study: 30803843
Drug: Inactivated enterovirus
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated enterovirus A71 vaccine
Study: 29989868
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of chelated zinc gluconate for one month
Study: 22805391
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sublingual isosorbide dinitrate (ISDN)
Study: 20824151
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pravastatin and Fenofibrate) from weeks 12-48
Study: 17099309
Drug: Amuchina 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amuchina 10% solution
Study: 12396323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DEC (6 mg/kg) and Albendazole (400 mg)
Study: 7597431
Drug: Paclitaxel 170
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 170 mg/m2 followed by ifosfamide 5 g/m2 divided over 3 days with mesna
Study: 724875
Drug: Directive therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directive therapy
Study: 724875
Drug: Interpretative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpretative therapy
Study: 23930635
Drug: Self-etching adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etching adhesive Adper Prompt L-Pop
Study: 21285943
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment (15 sessions separately for children and parents)
Study: 18811602
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of isotretinoin thrice a week for 3 months
Study: 18811602
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of isotretinoin thrice a week for 3 months
Study: 18811602
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 20 mg of isotretinoin
Study: 17350990
Drug: lopinavir/ritonavir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir + saquinavir (400/100 mg + 800 mg)
Study: 17350990
Drug: lopinavir/ritonavir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir + zidovudine/lamivudine (400/100 mg + 150/300 mg)
Study: 17350990
Drug: lopinavir/ritonavir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir + saquinavir (600 or 800 mg)
Study: 11883998
Drug: rhGH (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (13 IU/m(2) for 4 days) + glutamine-enriched TPN (7 g GLN/m(2)/day)
Study: 9630144
Drug: Mixed endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed endurance and calisthenic/strength activities performed at a rapid pace three times weekly for 12 weeks
Study: 8166318
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light therapy (10,000 lux for 30 min/day)
Study: 8166318
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light therapy (500 lux for 30 min/day)
Study: 8166318
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light therapy (10,000 lux for 30 min/day) in patients with seasonal bulimia
Study: 8166318
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light therapy (10,000 lux for 30 min/day) in patients with nonseasonal bulimia
Study: 3284292
Drug: Captopril (12.5‐25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5‐25 mg b.d.)
Study: 28537969
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% solution (saline group)
Study: 26625505
Drug: Co-payment reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-payment reduction from $8 to $0 per medication per month for antihypertensive prescriptions
Study: 15690268
Drug: Fentanyl 20
Normalized name: fentaNYL 200 mcg buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 20 microg mixed with hyperbaric ropivacaine 10 mg (group FR10)
Study: 15690268
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 15 mg (group R15)
Study: 10569649
Drug: TNK-tPA 40
Normalized name: TNK-tPA
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNK-tPA 40 mg
Study: 10569649
Drug: Mid-dose tertile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose tertile (0.40 to 0.51 mg/kg)
Study: 10569649
Drug: High-dose tertile
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tertile (0.52 to 1.24 mg/kg)
Study: 10569649
Drug: Low-dose tertile
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tertile (0.2 to 0.39 mg/kg)
Study: 10569649
Drug: High-dose and
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose and mid-dose tertiles
Study: 1844195
Drug: Biological monitoring
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological monitoring (cervical mucus) for HCG administration
Study: 1844195
Drug: Biochemical monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biochemical monitoring for HCG administration
Study: 6996111
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement (15 mg folic acid per day for 5 weeks)
Study: 23415641
Drug: BRAF inhibitors
Normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF inhibitors
Study: 31826931
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BRAF inhibition and TP53 reactivation
Study: 31826931
Drug: Tissue-specific mutation–drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-specific mutation–drug associations
Study: 28975664
Drug: Torasemide q24h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide q24h (median dose = 0.24 mg/kg/d; range = 0.10–0.69 mg/kg/d)